Form 4: TPG GP A Sells 250,000 Sionna Therapeutics Shares

TPG GP A, a 10% owner and director of Sionna Therapeutics, Inc., reported the sale of 250,000 shares of common stock at $40 per share.

Summary

• TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, reported a sale of Sionna Therapeutics, Inc. common stock.
• On January 22, 2026, 250,000 shares of common stock were disposed of at a price of $40 per share.
• Following this transaction, the reporting persons indirectly beneficially own 6,494,962 shares of Sionna Therapeutics common stock.
• The shares are held by The Rise Fund Sling, L.P. (5,340,931 shares) and The Rise Fund Sling II, L.P. (1,154,031 shares), which are TPG Funds.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The sale of 250,000 shares by a 10% owner and director, TPG GP A, LLC, could be perceived as a slightly negative signal by the market, although it was made pursuant to a Rule 10b5-1 plan. The transaction price of $40 per share is a factual report of the sale.

Negatives

• A 10% owner and director, TPG GP A, LLC, disposed of a significant number of shares (250,000) in Sionna Therapeutics, which could be perceived negatively by the market.

Future Outlook

NA

Management Comments

• Each of the TPG Funds and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any.

Industry Context

NA

Related Party Transactions

• The transaction involves TPG GP A, LLC, a 10% owner and director, and entities controlled by James G. Coulter and Jon Winkelried, who are also directors, selling shares of Sionna Therapeutics.

Stakeholder Impact

• Shareholders: The sale by a significant insider could lead to negative sentiment or questions about the company's future prospects, potentially impacting share price.

Key Dates

Recommendation

While a significant insider sale by a 10% owner and director could be viewed negatively, this transaction was made pursuant to a Rule 10b5-1 plan, which suggests it was pre-scheduled and not necessarily indicative of new negative information. Without further context on the company's financial performance, market conditions, or the insider's overall holdings and investment strategy, a 'hold' recommendation is prudent. Investors should monitor future insider activity and company developments.

Keywords

Sionna Therapeutics, SION, TPG GP A, Insider Sale, Form 4, Beneficial Ownership, Common Stock, Director Sale, 10% Owner